AIM: To investigate the efficacy and safety of cape-citabine plus irinotecan +/- bevacizumab in advanced or metastatic colorectal cancer patients. METHODS:Forty six patients with previously untreated, locally-advanced or metastatic colorectal cancer (mCRC) were recruited between 2001-2006 in a prospective open-label phase II trial, in German community-based outpatient clinics. Patients received a standard capecitabine plus irinotecan (CAPIRI) or CAPIRI plus bevacizumab (CAPIRI-BEV) regimen every 3 wk. Dose reductions were mandatory from the first cycle in cases of > grade 2 toxicity. The treatment choice of bevacizumab was at the discretion of the physician. The primary endpoints were response and toxicity and secondary endpoints included progression-free survival and overall survival. RESULTS: In the CAPIRI group vs the CAPRI-Bev group there were more female than male patients (47% vs 24%), and more patients had colon as the primary tumor site (58.8% vs 48.2%) with fewer patients having sigmoid colon as primary tumor site (5.9% vs 20.7%). Grade 3/4 toxicity was higher with CAPIRI than CAPIRI-Bev: 82% vs 58.6%. Partial response rates were 29.4% and 34.5%, and tumor control rates were 70.6% and 75.9%, respectively. No complete responses were observed. The median progression-free survival was 11.4 mo and 12.8 mo for CAPIRI and CAPIRI-Bev, respectively. The median overall survival for CAPIRI was 15 mo (458 d) and for CAPIRI-Bev 24 mo (733 d). These differences were not statistically different. In the CAPIRI-Bev, group, two patients underwent a full secondary tumor resection after treatment, whereas in the CAPIRI group no cases underwent this procedure. CONCLUSION: Both regimens were well tolerated and offered effective tumor growth control in this outpatient setting. Severe gastrointestinal toxicities and thromboembolic events were rare and if observed were never fatal.
RCT Entities:
AIM: To investigate the efficacy and safety of cape-citabine plus irinotecan +/- bevacizumab in advanced or metastatic colorectal cancerpatients. METHODS: Forty six patients with previously untreated, locally-advanced or metastatic colorectal cancer (mCRC) were recruited between 2001-2006 in a prospective open-label phase II trial, in German community-based outpatient clinics. Patients received a standard capecitabine plus irinotecan (CAPIRI) or CAPIRI plus bevacizumab (CAPIRI-BEV) regimen every 3 wk. Dose reductions were mandatory from the first cycle in cases of > grade 2 toxicity. The treatment choice of bevacizumab was at the discretion of the physician. The primary endpoints were response and toxicity and secondary endpoints included progression-free survival and overall survival. RESULTS: In the CAPIRI group vs the CAPRI-Bev group there were more female than male patients (47% vs 24%), and more patients had colon as the primary tumor site (58.8% vs 48.2%) with fewer patients having sigmoid colon as primary tumor site (5.9% vs 20.7%). Grade 3/4 toxicity was higher with CAPIRI than CAPIRI-Bev: 82% vs 58.6%. Partial response rates were 29.4% and 34.5%, and tumor control rates were 70.6% and 75.9%, respectively. No complete responses were observed. The median progression-free survival was 11.4 mo and 12.8 mo for CAPIRI and CAPIRI-Bev, respectively. The median overall survival for CAPIRI was 15 mo (458 d) and for CAPIRI-Bev 24 mo (733 d). These differences were not statistically different. In the CAPIRI-Bev, group, two patients underwent a full secondary tumor resection after treatment, whereas in the CAPIRI group no cases underwent this procedure. CONCLUSION: Both regimens were well tolerated and offered effective tumor growth control in this outpatient setting. Severe gastrointestinal toxicities and thromboembolic events were rare and if observed were never fatal.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: P M Hoff; R Ansari; G Batist; J Cox; W Kocha; M Kuperminc; J Maroun; D Walde; C Weaver; E Harrison; H U Burger; B Osterwalder; A O Wong; R Wong Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: E Van Cutsem; C Twelves; J Cassidy; D Allman; E Bajetta; M Boyer; R Bugat; M Findlay; S Frings; M Jahn; J McKendrick; B Osterwalder; G Perez-Manga; R Rosso; P Rougier; W H Schmiegel; J F Seitz; P Thompson; J M Vieitez; C Weitzel; P Harper Journal: J Clin Oncol Date: 2001-11-01 Impact factor: 44.544
Authors: L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller Journal: N Engl J Med Date: 2000-09-28 Impact factor: 91.245
Authors: A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti Journal: J Clin Oncol Date: 2000-08 Impact factor: 44.544
Authors: J Cassidy; C Twelves; E Van Cutsem; P Hoff; E Bajetta; M Boyer; R Bugat; U Burger; A Garin; U Graeven; J McKendric; J Maroun; J Marshall; B Osterwalder; G Pérez-Manga; R Rosso; P Rougier; R L Schilsky Journal: Ann Oncol Date: 2002-04 Impact factor: 32.976
Authors: Markus Moehler; Tanja Hoffmann; Christine Zanke; Horst Hohl; Helmut Burg; Peter Ehscheid; Peter Schwindt; Bernd Adami; Martin Schroeder; Ortwin Klein; Michael Baldus; Peter R Galle; Michael Heike Journal: Anticancer Drugs Date: 2003-01 Impact factor: 2.248
Authors: Howard S Hochster; Lowell L Hart; Ramesh K Ramanathan; Barrett H Childs; John D Hainsworth; Allen L Cohn; Lucas Wong; Louis Fehrenbacher; Yousif Abubakr; M Wasif Saif; Lee Schwartzberg; Eric Hedrick Journal: J Clin Oncol Date: 2008-07-20 Impact factor: 44.544
Authors: M Tewes; N Schleucher; W Achterrath; H J Wilke; S Frings; S Seeber; A Harstrick; Y M Rustum; U Vanhoefer Journal: Ann Oncol Date: 2003-09 Impact factor: 32.976
Authors: Fairooz Kabbinavar; Herbert I Hurwitz; Louis Fehrenbacher; Neal J Meropol; William F Novotny; Grazyna Lieberman; Susan Griffing; Emily Bergsland Journal: J Clin Oncol Date: 2003-01-01 Impact factor: 44.544
Authors: Efstathios T Pavlidis; Konstantinos D Ballas; Nikolaos G Symeonidis; Kyriakos Psarras; Georgios Koliakos; Kokona Kouzi-Koliakos; Konstantina Topouridou; Savas F Rafailidis; Theodoros E Pavlidis; Georgios N Marakis; Athanasios K Sakantamis Journal: Int J Colorectal Dis Date: 2010-08-06 Impact factor: 2.571
Authors: C P Escalante; Y C Chang; K Liao; T Rouleau; J Halm; P Bossi; S Bhadriraju; N Brito-Dellan; S Sahai; S W Yusuf; A Zalpour; L S Elting Journal: Support Care Cancer Date: 2016-06-25 Impact factor: 3.603
Authors: Linda S Elting; Yu-Chia Chang; Pratibha Parelkar; Christine B Boers-Doets; Marisol Michelet; Guido Hita; Tanya Rouleau; Catherine Cooksley; Josiah Halm; Madhuri Vithala; Paolo Bossi; Carmen Escalante; Michael T Brennan Journal: Support Care Cancer Date: 2013-05-02 Impact factor: 3.603
Authors: M Degirmenci; B Karaca; G Gorumlu; R Durusoy; G Demir Piskin; M T Bozkurt; Y Cirak; D Tunali; B Karabulut; U A Sanli; R Uslu Journal: Med Oncol Date: 2009-06-13 Impact factor: 3.064
Authors: Dimitrios Pectasides; George Papaxoinis; Konstantine T Kalogeras; Anastasia G Eleftheraki; Ioannis Xanthakis; Thomas Makatsoris; Epaminondas Samantas; Ioannis Varthalitis; Pavlos Papakostas; Nikitas Nikitas; Christos N Papandreou; George Pentheroudakis; Eleni Timotheadou; Angelos Koutras; Joseph Sgouros; Dimitrios Bafaloukos; George Klouvas; Theofanis Economopoulos; Konstantinos N Syrigos; George Fountzilas Journal: BMC Cancer Date: 2012-06-29 Impact factor: 4.430